Clinical Trial Update: Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification [Phase 2]

View source ↗

Summary

Phase 2 trial of osimertinib combined with savolitinib for non-small cell lung cancer with MET amplification; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Savolitinib (savolitinib)

Snippet

Sponsor: Qingdao Central Hospital | Conditions: EGFR Positive Non-small Cell Lung Cancer, MET Amplification | Phase 2 | Status: RECRUITING